Schott Pharma
Schott Pharma is a German provider of glass and polymer containment and delivery systems for injectable medicines.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Schott Pharma is a pharmaceutical packaging and drug-delivery company headquartered in Mainz, Germany. It supplies containment and administration systems used by pharmaceutical manufacturers for injectable medicines, including vials, cartridges, ampoules, prefillable glass syringes and polymer-based syringes. Its role is primarily business-to-business: the company provides components and systems that help preserve drug quality, support filling and administration processes, and accommodate specialized products such as medicines requiring deep-cold storage. The company developed from the pharmaceutical activities of SCHOTT AG, a specialty-glass manufacturer. Its industrial background reaches back to the work of Otto Schott, who developed borosilicate glass in the late nineteenth century. SCHOTT began producing borosilicate-glass tubing for pharmaceutical ampoules and vials in 1911. This long history in pharmaceutical glass provided the technical and manufacturing foundation for the later standalone company, although Schott Pharma itself was established as a separate corporate entity only in 2022. Schott Pharma was created through an equity carve-out from SCHOTT AG under the legal name Schott Pharma AG & Co. KGaA. The separation was intended to establish the pharmaceutical packaging activities as a more focused business while retaining SCHOTT AG as the controlling shareholder. Plans for a public offering were announced in 2022, but the offering was reportedly deferred amid market uncertainty following Russia's invasion of Ukraine. In June 2023, the company announced a renewed plan for an initial public offering, which was completed in September 2023 on the Frankfurt Stock Exchange. The offering was described as Germany's largest IPO of 2023. SCHOTT AG retained control after the flotation. The business is organized around two principal divisions. Drug Containment Solutions covers pharmaceutical vials, cartridges and glass ampoules. Drug Delivery Systems covers prefillable glass syringes and syringes made from cyclic olefin copolymer, a polymer material used in applications where dimensional stability, break resistance or low-temperature performance are important. These products serve pharmaceutical and biotechnology customers rather than end consumers, and their specifications are closely tied to drug formulation, filling technology, sterilization, storage and administration requirements. Manufacturing and technology activities extend across Europe, North America, South America and Asia. The company's listed production and technology locations include a major site in Müllheim, Germany, as well as facilities in Hungary, Switzerland, Serbia, the United States, China and other markets. In the United States, locations identified in the reference material include Wilson, North Carolina, and Lebanon, Pennsylvania. This geographic footprint allows Schott Pharma to support multinational pharmaceutical customers and to produce close to important drug-manufacturing markets. After its listing, the company entered the SDAX in December 2023 and was included in the MDAX between September 2024 and March 2025, according to the referenced account. Schott Pharma remains a subsidiary of SCHOTT AG, which in turn is owned by the Carl Zeiss Foundation. Its strategic identity is therefore that of a specialized, globally oriented pharmaceutical-component supplier operating within a larger German technology and materials group. The brand is associated with high-specification primary packaging, industrial reliability and systems designed for injectable-drug development and production.
History
Schott Pharma's origins lie in the development of specialty glass associated with SCHOTT AG. In 1887, Otto Schott developed borosilicate glass, a material valued for its resistance to thermal shock and chemical attack. These properties made it useful for laboratory equipment and, later, pharmaceutical packaging. From 1911, SCHOTT manufactured borosilicate-glass tubing used to produce pharmaceutical ampoules and vials. That activity established a technical and industrial link between the SCHOTT group and the pharmaceutical-packaging market that continued for more than a century. The modern Schott Pharma business was formed in 2022 through an equity carve-out from SCHOTT AG. It was incorporated as Schott Pharma AG & Co. KGaA and became a standalone corporate vehicle for SCHOTT's pharmaceutical containment and delivery activities. The separation did not end the relationship with SCHOTT AG: SCHOTT remained the controlling shareholder, while the wider group continued to be owned by the Carl Zeiss Foundation. The carve-out gave the pharmaceutical operation a more distinct corporate identity and created a structure suitable for a future public listing. Schott Pharma announced an IPO plan in 2022. The planned transaction was reportedly postponed to 2023 amid difficult capital-market conditions following Russia's invasion of Ukraine. In June 2023, the company announced that it intended to revive the offering and target a September flotation. The IPO was completed in September 2023 on the Frankfurt Stock Exchange. The initial offer price was reported as €27 per share, with a potential valuation of up to €4.1 billion; the reference material also reports that the share price reached €30 on the following day. Because these are transaction-specific historical figures, they should be understood in the context of the 2023 offering rather than as current financial information. The listing was characterized as Germany's largest IPO of 2023. Following the flotation, Schott Pharma became part of the German equity-index system. It entered the SDAX in December 2023 and was subsequently included in the MDAX between September 2024 and March 2025, according to the referenced Wikipedia account. The company therefore evolved from a division within a specialty-glass group into a separately listed pharmaceutical-technology company while retaining a controlling parent. Operationally, the company is divided into Drug Containment Solutions and Drug Delivery Systems. The first division supplies primary containers such as vials, cartridges and glass ampoules. The second supplies prefillable glass syringes and syringes made from cyclic olefin copolymer, a polymer suitable for selected pharmaceutical applications, including products exposed to very low temperatures. The products are intended for pharmaceutical and biotechnology manufacturing, where container compatibility, integrity, sterility, filling performance and storage conditions are critical. Schott Pharma's manufacturing network extends across Europe, North America, South America and Asia. The reference material identifies a production and technology centre in Müllheim, Germany, and operations in Hungary, Switzerland, Serbia, the United States and China. U.S. locations include Wilson, North Carolina, and Lebanon, Pennsylvania. This network supports the company's role as an international supplier to drug manufacturers and reflects the need for pharmaceutical-packaging production to operate close to global customers and regulated manufacturing ecosystems.
- 2025
End of reported MDAX inclusion
[1]The reference material states that the company remained in the MDAX through March 2025.
- 2024
Admission to the MDAX
[1]Schott Pharma entered the MDAX in September 2024, according to the referenced account.
- 2023
Initial public offering on the Frankfurt Stock Exchange
[1]Schott Pharma completed its IPO in September 2023, becoming a separately listed company while SCHOTT AG retained control.
- 2023
Admission to the SDAX
[1]The company was included in the SDAX in December 2023.
- 2022
Schott Pharma is established as a standalone company
[1]Schott Pharma AG & Co. KGaA was formed through an equity carve-out from SCHOTT AG.
- 1911
SCHOTT begins pharmaceutical glass tubing production
[1]SCHOTT began manufacturing borosilicate-glass tubing for pharmaceutical ampoules and vials.
- 1887
Otto Schott develops borosilicate glass
[1]Otto Schott developed borosilicate glass, establishing the material-science foundation associated with the later SCHOTT pharmaceutical-packaging business.
Products and positioning
A specialized business-to-business supplier of high-performance primary containers and delivery systems for injectable pharmaceuticals, combining pharmaceutical-glass expertise with polymer-based delivery technologies and international manufacturing.
Drug containment
Pharmaceutical vials
Glass vials are primary pharmaceutical containers used for injectable medicines. Schott Pharma's vial business draws on the SCHOTT group's long history in borosilicate glass and serves drug manufacturers that require containers with controlled material properties, reliable dimensional performance and suitability for filling, sterilization, storage and clinical or commercial administration.
Drug containment
Pharmaceutical cartridges
Pharmaceutical cartridges are containers designed for medicines administered through compatible injection devices. They form part of Schott Pharma's Drug Containment Solutions portfolio and are supplied as industrial components for pharmaceutical filling and delivery processes, where container integrity, drug compatibility and consistent manufacturing are important.
Drug containment
Glass ampoules
Glass ampoules provide sealed single-dose or small-volume containment for pharmaceutical products. They are part of the company's established glass-packaging activities, whose historical roots extend to SCHOTT's production of borosilicate tubing for ampoules beginning in 1911.
Drug delivery
Prefillable glass syringes
Prefillable glass syringes are supplied ready for pharmaceutical manufacturers to fill before distribution or use. They combine primary containment with a delivery format and are intended to support injectable medicines that require controlled filling, storage and administration through a syringe-based presentation.
Drug delivery
Cyclic olefin copolymer syringes
Cyclic olefin copolymer syringes use a specialized polymer platform for selected injectable-drug applications. The reference material identifies them as suitable for deep-cold medications, making them relevant to drug products whose storage or handling requirements place unusual demands on the delivery container.
Brand decisions
2023
Proceed with the initial public offeringOtherBackground
The company's IPO plan announced in 2022 had reportedly been postponed amid market uncertainty.
Action taken
In June 2023, Schott Pharma announced a September IPO and completed the listing on the Frankfurt Stock Exchange that month.
Aftermath
Schott Pharma became a publicly traded company, while SCHOTT AG remained its controlling shareholder. The transaction was reported as Germany's largest IPO of 2023.
IPO offer price and potential valuation. €27 per share; potential valuation of up to €4.1 billion at the offering → €30 per share on the day after the IPO, as reported in the reference material (September 2023)
2022
Create a standalone pharmaceutical company through an equity carve-outStrategyBackground
SCHOTT AG's pharmaceutical containment and delivery activities were separated into a dedicated company as Schott Pharma AG & Co. KGaA.
Action taken
The new company was established as a standalone corporate entity while SCHOTT AG retained a controlling ownership position.
Aftermath
The carve-out provided the basis for an independent corporate profile and the subsequent 2023 stock-market listing.
Recent events
- 2024
Schott Pharma included in the MDAX[1]
Other
The company was included in the MDAX from September 2024, according to the referenced account, before leaving the index in March 2025.
- 2023
Schott Pharma renews IPO plans[1]
Other
In June 2023, Schott Pharma announced that it intended to proceed with an initial public offering in September.
- 2023
Schott Pharma completes Frankfurt listing[1]
Other
Schott Pharma completed its initial public offering on the Frankfurt Stock Exchange in September 2023. The transaction was described in the reference material as Germany's largest IPO of the year.
- 2023
Schott Pharma joins the SDAX[1]
Other
The company was added to Germany's SDAX index in December 2023 following its stock-market listing.
- 2023
SCHOTT Pharma completes Frankfurt IPO[1]
M&A · Other
SCHOTT Pharma went public on the Frankfurt Stock Exchange in September 2023 after announcing the offering in June. The initial offer price was reported as 27 euros per share.
- 2022
Schott Pharma announces plans for an initial public offering[1]
Other
The newly established pharmaceutical company announced plans to pursue a public offering after being separated from SCHOTT AG. The offering was subsequently reported as postponed amid market uncertainty connected with the Russian invasion of Ukraine.
- 2022
SCHOTT Pharma establishes itself as a standalone company[1]
M&A · Other
The pharmaceutical business was established as Schott Pharma AG & Co. KGaA through an equity carve-out from SCHOTT AG.
- 2022
Planned SCHOTT Pharma IPO delayed[1]
Other
The company announced plans for a public offering, but the offering was reportedly postponed to 2023 amid market disruption associated with the Russian invasion of Ukraine.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/schott-pharma · Editorial policy · How profiles are compiled